Merck Gains Phase III Drug/Companion Diagnostic In Deal With Endocyte

Merck will acquire rights to develop and commercialize Endocyte’s vintafolide, in Phase III development for ovarian cancer, in exchange for $120 million upfront and up to $880 million in milestones.